Last reviewed · How we verify
Topotecan and pegylated doxorubicin
Topotecan and pegylated doxorubicin is a Small molecule drug developed by Christiana Care Health Services. It is currently in Phase 1 development. Also known as: Hycamptin Topoisomerase I inhibitor.
At a glance
| Generic name | Topotecan and pegylated doxorubicin |
|---|---|
| Also known as | Hycamptin Topoisomerase I inhibitor |
| Sponsor | Christiana Care Health Services |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (PHASE2, PHASE3)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (PHASE2)
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (PHASE3)
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (PHASE2, PHASE3)
- MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer (PHASE2)
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (PHASE2, PHASE3)
- REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topotecan and pegylated doxorubicin CI brief — competitive landscape report
- Topotecan and pegylated doxorubicin updates RSS · CI watch RSS
- Christiana Care Health Services portfolio CI
Frequently asked questions about Topotecan and pegylated doxorubicin
What is Topotecan and pegylated doxorubicin?
Topotecan and pegylated doxorubicin is a Small molecule drug developed by Christiana Care Health Services.
Who makes Topotecan and pegylated doxorubicin?
Topotecan and pegylated doxorubicin is developed by Christiana Care Health Services (see full Christiana Care Health Services pipeline at /company/christiana-care-health-services).
Is Topotecan and pegylated doxorubicin also known as anything else?
Topotecan and pegylated doxorubicin is also known as Hycamptin Topoisomerase I inhibitor.
What development phase is Topotecan and pegylated doxorubicin in?
Topotecan and pegylated doxorubicin is in Phase 1.
Related
- Manufacturer: Christiana Care Health Services — full pipeline
- Also known as: Hycamptin Topoisomerase I inhibitor
- Compare: Topotecan and pegylated doxorubicin vs similar drugs
- Pricing: Topotecan and pegylated doxorubicin cost, discount & access